Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies: Are clinicians responding optimally?

Journal of the American College of Cardiology

Volumn 56, Issue 20, 2010, Pages 1644-1650

  Yoon, Geoffrey J ^a   Telli, Melinda L ^a   Kao, David P ^b   Matsuda, Kelly Y ^a   Carlson, Robert W ^a   Witteles, Ronald M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Anthracyclines; Cancer; Chemotherapy; Heart failure; Left ventricular dysfunction

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTHRACYCLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DAUNORUBICIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; BREAST CANCER; CANCER SURVIVOR; CANCER THERAPY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CHRONIC MYELOID LEUKEMIA; CONSULTATION; DISEASE CLASSIFICATION; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYMPTOMATOLOGY; ARTICLE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; ECHOGRAPHY; FOLLOW UP; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HEART VENTRICLE; MIDDLE AGED; NEOPLASM; PATHOPHYSIOLOGY; PROGNOSIS; RETROSPECTIVE STUDY;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT; YOUNG ADULT;

EID: 78751677515     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.07.023     Document Type: Review

References (27)

1. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009;53:e1-90.
2. Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 2003;108:977-82. (Pubitemid 37048228)
3. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
4. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302-14.
5. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91:710 -7. (Pubitemid 10218041)
6. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. 28 May 2009. Available at: http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/ docs/ctcaev4.pdf. Accessed October 10, 2009.
7. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869 -79. (Pubitemid 36605157)
8. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92. (Pubitemid 32222155)
9. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al., Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659 -72. (Pubitemid 41464705)
10. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811-9. (Pubitemid 46657378)
11. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84. (Pubitemid 41464706)
12. Slamon DJ, Eiermann W, Robert N, Pienkowski T. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide with docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2-positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005;94:S5.
13. Slamon DJ, Eiermann W, Robert N, Pienkowski T, Martin M. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Paper presented at: 29th Annual San Antonio Breast Cancer Symposium; December 15, 2006; San Antonio, TX
14. Smith I, Procter M, Gelber RD, Guillaume S, Fevereislova A, Dowsett M. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29 -36. (Pubitemid 46039831)
15. Herceptin (trastuzumab) package insert. South San Francisco, CA: Genentech, Incorporated; March 2009.
16. Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumabrelated cardiotoxicity: Calling into question the concept of reversibility. J Clin Oncol 2007;25:3525-33. (Pubitemid 47310891)
17. Hospital Compare. U.S. Department of Health & Human Services, 2009. Available at: http://www.hospitalcompare.hhs.gov/Hospital/ Search/SearchMethod. asp. Accessed September 15, 2009.
18. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
19. Indridason OS, Coffman CJ, Oddone EZ. Is specialty care associated with improved survival of patients with congestive heart failure? Am Heart J 2003;145:300 -9. (Pubitemid 36207952)
20. Nousiainen T, Jantunen E, Vanninen E, Hartikainen J. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer 2002;86:1697-700. (Pubitemid 34712910)
21. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002;13:699-709. (Pubitemid 34567375)
22. Haq MM, Legha SS, Choksi J, et al. Doxorubicin-induced congestive heart failure in adults. Cancer 1985;56:1361-5. (Pubitemid 15230583)
23. Douglas PS, Khandheria B, Stainback RF, et al. ACCF/ASE/ACEP/ ASNC/SCAI/SCCT/SCMR 2007 appropriateness criteria for transthoracic and transesophageal echocardiography: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American Society of Echocardiography, American College of Emergency Physicians, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol 2007;50:187-204.
24. Hequet O, Le QH, Moullet I, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 2004;22:1864 -71. (Pubitemid 41095177)
25. Hershman DL, McBride RB, Eisenberger A, Tsai WY, Grann VR, Jacobson JS. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26:3159-65.
26. Shapiro CL, Hardenbergh PH, Gelman R, et al. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol 1998;16:3493-501. (Pubitemid 28506759)
27. Riad A, Bien S, Westermann D, et al. Pretreatment with statin attenuates the cardiotoxicity of Doxorubicin in mice. Cancer Res 2009;69:695-9.